It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
A cross-diagnostic, post-hoc analysis of the BRIDGE-II-MIX study was performed to investigate how unipolar and bipolar patients suffering from an acute major depressive episode (MDE) cluster according to severity and duration. Duration of index episode, Clinical Global Impression-Bipolar Version-Depression (CGI-BP-D) and Global Assessment of Functioning (GAF) were used as clustering variables. MANOVA and post-hoc ANOVAs examined between-group differences in clustering variables. A stepwise backward regression model explored the relationship with the 56 clinical-demographic variables available. Agglomerative hierarchical clustering with two clusters was shown as the best fit and separated the study population (n = 2314) into 65.73% (Cluster 1 (C1)) and 34.26% (Cluster 2 (C2)). MANOVA showed a significant main effect for cluster group (p < 0.001) but ANOVA revealed that significant between-group differences were restricted to CGI-BP-D (p < 0.001) and GAF (p < 0.001), showing greater severity in C2. Psychotic features and a minimum of three DSM-5 criteria for mixed features (DSM-5-3C) had the strongest association with C2, that with greater disease burden, while non-mixed depression in bipolar disorder (BD) type II had negative association. Mixed affect defined as DSM-5-3C associates with greater acute severity and overall impairment, independently of the diagnosis of bipolar or unipolar depression. In this study a pure, non-mixed depression in BD type II significantly associates with lesser burden of clinical and functional severity. The lack of association for less restrictive, researched-based definitions of mixed features underlines DSM-5-3C specificity. If confirmed in further prospective studies, these findings would warrant major revisions of treatment algorithms for both unipolar and bipolar depression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy (GRID:grid.6292.f) (ISNI:0000 0004 1757 1758); University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.6292.f)
2 University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.6292.f)
3 University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.6292.f); Biomedical Research Networking Center for Mental Health (CIBERSAM), Barcelona, Spain (GRID:grid.6292.f); August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain (GRID:grid.10403.36)
4 University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.10403.36)
5 University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.10403.36); Biomedical Research Networking Center for Mental Health (CIBERSAM), Barcelona, Spain (GRID:grid.10403.36); August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain (GRID:grid.10403.36)
6 Chaim Sheba Medical Center, Psychiatry B, Ramat-Gan, Israel (GRID:grid.413795.d) (ISNI:0000 0001 2107 2845)
7 Sainte Marguerite Hospital, Department of Psychiatry, Marseille, France (GRID:grid.414438.e) (ISNI:0000 0000 9834 707X)
8 University of Zurich, Department of Psychiatry, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
9 University of Texas Health Science Center, Department of Psychiatry, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880)
10 Moscow Research Institute of Psychiatry, Department for Therapy of Mental Disorders, Moscow, Russia (GRID:grid.473242.4)
11 Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
12 University of Pisa, Clinica Psichiatrica, Pisa, Italy (GRID:grid.5395.a) (ISNI:0000 0004 1757 3729)
13 University of Barcelona, IDIBAPS, CIBERSAM, Bipolar and Depressive Disorders Unit, Institute of Neuroscience, Hospital Clínic, Barcelona, Spain (GRID:grid.5395.a); Biomedical Research Networking Center for Mental Health (CIBERSAM), Barcelona, Spain (GRID:grid.5395.a); August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain (GRID:grid.10403.36)